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Synopsis 
 
 
 
 • Asparaginase is an effective drug for adolescent acute lymphoblastic leukemia treatment, 
but toxicity and tolerance hampered further usage in patients with solid tumors.  
• A genome-wide functional screen identifies SLC1A3 as a novel contributor to 
asparaginase resistance in cancer cells, in addition to the known ASNS and GCN2. 
• While SLC1A3 expression is typically restricted to brain tissues, high expression level is 
observed in several tumor types. 
• Combined SLC1A3 blockade with asparaginase treatment elicits cell cycle arrest and 
apoptosis in SLC1A3 positive cancer cells.  
• Replenishing intracellular aspartate and glutamate levels by SLC1A3 promotes cancer 
cell proliferation and metastasis, despite asparaginase-induced shortages. 
 
  
 Abstract 
L-asparaginase (ASNase) serves as an effective drug for adolescent acute lymphoblastic 
leukemia. However, many clinical trials indicated severe ASNase toxicity in patients with solid 
tumors, with resistant mechanisms not well understood. Here, we took a functional genetic 
approach and identified SLC1A3 as a novel contributor to ASNase resistance in cancer cells. In 
combination with ASNase, SLC1A3 inhibition caused cell cycle arrest or apoptosis, and myriads 
of metabolic vulnerabilities in tricarboxylic acid (TCA) cycle, urea cycle, nucleotides 
biosynthesis, energy production, oxidation homeostasis and lipid biosynthesis. SLC1A3 is an 
aspartate and glutamate transporter, mainly expressed in brain tissues, but high expression 
levels were also observed in some tumor types. Here, we demonstrate that ASNase stimulates 
aspartate and glutamate consumptions, and their refilling through SLC1A3 promotes cancer cell 
proliferation. Lastly, in vivo experiments indicated that SLC1A3 expression promoted tumor 
development and metastasis while negating the suppressive effects of ASNase by fueling 
aspartate, glutamate and glutamine metabolisms despite of asparagine shortage. Altogether, 
our findings identify a novel role for SLC1A3 in ASNase resistance and suggest that restrictive 
aspartate and glutamate uptake might improve ASNase efficacy with solid tumors. 
 
  
 Introduction 
Treating cancer with amino acid deprivation schemes has achieved limited clinical success so 
far. Only in acute lymphoblastic leukemia (ALL), the incorporation of L-asparaginase (ASNase) 
has significantly increased the overall survival rates to ~90% (Pui et al, 2009; Broome, 1961; 
Müller & J.Boos, 1998). ALL cells are auxotrophic for asparagine which was deaminated and 
depleted by the enzyme ASNase, resulting in cell cycle arrest and apoptosis in ALL cells without 
affecting normal tissues (Kidd, 1953; Broome, 1961; Pui et al, 2009; Ueno et al, 1997). Notably, 
ASNase has a dual asparagine and glutamine deaminase activity, however, its glutaminase 
activity was not required for anticancer effect in asparagine synthetase (ASNS) negative cancer 
cells (Chan et al, 2014). The therapeutic progress of ASNase in ALL had greatly encouraged its 
further application for solid tumors. However, many clinical trials reported intolerable toxicity in 
patients (Hays et al, 2013; Haskell et al, 1969). ASNS expression has been proposed as a 
marker for clinical prediction of ASNase resistance (Scherf et al, 2000), however, treatment of 
ALL with ASNase is still effective even though ASNS is expressed (Krall et al, 2016; Stams, 
2003; Vander Heiden & DeBerardinis, 2017). Interestingly, aspartate metabolism was also 
predicted to contribute to ASNase sensitivity according to a previous study (Chen et al, 2011). 
Overall, with the exception of ASNS, little is known about the specific resistant mechanisms to 
ASNase, which has hindered the attempts to broaden ASNase’s benefits to patients with solid 
tumors (Hays et al, 2013; Kidd, 1953; Haskell et al, 1969; Vander Heiden & DeBerardinis, 
2017). 
 
Our previous work has found that ASNase treatment of PC3, a prostate cancer cell line, 
triggered asparagine shortage accompanied by increased asparagine production through 
upregulation of ASNS, as indicated by ribosomal and transcriptional profiling (Loayza-Puch et 
al, 2016). This pinpointed a feedback loop under asparagine depleted conditions. Yet, PC3 cells 
remained proliferative despite of asparagine shortage, suggesting the involvement of other 
mechanisms responsible for ASNase resistance as upregulated ASNS was not sufficient for 
asparagine replenishment. Therefore, we used a functional genetic screen in PC3 cells to 
explore potential vulnerabilities in solid cancer cells to ASNase treatment. We identified 
SLC1A3, an aspartate/glutamate transporter, as a novel contributor in ASNase resistance, as 
well as tumor initiation and progression in a mice model for breast cancer metastasis.  
 
  
 Results 
A Genome-wide CRISPR-Cas9 screen identifies SLC1A3 as a novel contributor to 
ASNase resistance in PC3 cells 
To determine the optimal ASNase concentration required for performing a genome-wide 
functional screen, we tested a series of ASNase concentrations in PC3 cells. Fig 1A shows that 
ASNase at a concentration of 0.3~0.5 U/ml moderately inhibited cell proliferation. As this 
dosage is within the range used for asparagine depletion in some ALL patients according to 
previous research (Riccardi et al, 1981; Avramis & Panosyan, 2005), we performed the screen 
and in vitro validation under this condition. Due to its essential role in asparagine synthesis, 
ASNS gene was used as a positive control for the screen. As expected, CRISPR-Cas9 
knockout (KO) of ASNS sensitized PC3 cells to ASNase treatment but did not affect cell 
proliferation under mock-treatment (Fig 1B). 
 
Next, we transduced a genome-wide CRISPR-Cas9 library, consisting of 76,441 single guide 
RNAs (sgRNAs) targeting 19,114 genes, into PC3 cells, which were further divided into mock 
and ASNase treated conditions (Fig 1C). Following 20 days of culturing, cells were harvested 
and subjected to deep sequencing of integrated sgRNAs and MAGeCK bioinformatics analysis 
of individual sgRNA abundance. Intriguingly, in addition to the expected ASNS gene, this 
analysis proposed 4 additional genes (FDR<0.003, Fig 1D), whose loss-of-function may impair 
PC3 cell proliferation following ASNase treatment. Follow-up validations using individual 
CRISPR vector transductions and cell competitive growth assays successfully validated three 
out of the four additional hits: EIF2AK4 (GCN2, general control nonderepressible 2), SLC1A3 
and SLC25A1 (Figs 1D and EV1A), highlighting the reliability of the screen. Notably, EIF2AK4 
was also predictable due to its role in regulating general nutrient deprivation responses (Bunpo 
et al, 2009; Ye et al, 2010). The other two hits (SLC1A3 and SLC25A1) are both from the solute 
carrier family (SLC). SLC1A3 functions as a high-affinity aspartate and glutamate transporter, 
whose loss-of-function triggered a marked reduction in cell survival and proliferation following 
ASNase treatment (Figs 1E and EV1B). SLC25A1, a mitochondria citrate carrier, whose loss of 
function also caused inhibitory effects on cell survival and proliferation in the presence of 
ASNase, but to a more moderate extent when compared with that of SLC1A3 (Fig EV1A). Due 
to the relatively strong synergistic effect, from now on, we only focused on the role of SLC1A3 in 
the context of ASNase.  
 
 SLC1A3 is mainly expressed in brain tissues (Fig EV1C), critical for the termination of excitatory 
neurotransmission (Kanai et al, 2013). Recent studies have highlighted the importance of 
SLC1A3-mediated aspartate uptake for cancer cell proliferation under hypoxia and crosstalk 
between cancer cells and cancer associated fibroblasts in the tumor niche (Garcia-Bermudez et 
al, 2018; Sullivan et al, 2018; Tajan et al, 2018; Alkan et al, 2018; Bertero et al, 2019). We also 
observed elevated SLC1A3 RNA levels in several tumor types from the TCGA database 
(especially kidney renal clear cell carcinoma (KIRC, p = 5.5 × 10-30), kidney renal papillary cell 
carcinoma (KIRP, p = 2.1 × 10-10), liver hepatocellular carcinoma (LIHC, p = 3.2 × 10-10) and 
stomach adenocarcinoma (STAD, p = 6.1 × 10-5)) (Fig EV1D).  
 
To examine the function of SLC1A3, we tested its cellular aspartate/glutamate transporting 
function using a radioactive labeled amino acid uptake assay as previously described (Loayza‐
Puch et al, 2017). As predicted, SLC1A3 loss-of-function reduced both aspartate and glutamate 
uptake in PC3 cells (Fig 1F), also leading to decreased endogenous aspartate (~8-fold) and 
glutamate (~1.5-fold) levels (Fig 1G). Following ASNase treatment in control PC3 cells, we 
observed strong depletions of both asparagine and glutamine (Fig 1G), in concordance with its 
known dual functions. This was followed by a significant reduction in endogenous aspartate and 
glutamate levels (Fig 1G), indicating a stimulated demand for aspartate and glutamate. 
Consequently, in SLC1A3-KO PC3 cells, aspartate and glutamate levels was further depleted 
under ASNase treatment (~16-fold for aspartate and ~3-fold for glutamate, Fig 1G). This 
observation suggests that SLC1A3-mediated aspartate and glutamate import is required for the 
maintenance of sufficient intracellular aspartate and glutamate pools to survive ASNase 
treatment. Of note, the endogenous glutamine level was significantly depleted in SLC1A3-KO 
PC3 cells, but this had no effect on cell proliferation in the absence of ASNase (Figs 1G and 
1E). To directly test the functions of aspartate and glutamate in the context of ASNase, we 
supplemented SLC1A3-KO PC3 cells with cell-permeable forms of aspartate and glutamate 
(esterified). Fig 1H shows that both esterified aspartate and esterified glutamate, but not 
esterified leucine, can restore SLC1A3-KO PC3 cell proliferation in the presence of ASNase. 
Lastly, we examined a possible role of SLC1A3 to ASNase treatment in vivo. We 
subcutaneously implanted control and SLC1A3-KO PC3 cells into Balb/c nude mice (cAnN/Rj) 
and examined tumor growth in the absence and presence of ASNase. Fig EV1E shows that loss 
of SLC1A3 in combination of ASNase treatment impeded tumor growth. Altogether, we 
conclude that SLC1A3 expression negates the impact of ASNase on PC3 cell survival, 
proliferation and efficient tumor growth. 
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 Figure 1. A genome-wide CRISPR-Cas9 screen identifies SLC1A3 as a contributor to L-
asparaginase (ASNase) resistance in PC3 cells. 
A. IncuCyte cell proliferation curves of PC3 cells treated with the indicated concentrations of 
ASNase.  
B. IncuCyte cell proliferation curves for ASNS knockout (sgASNS) and control (sgNon-targeting) 
PC3 cells in the absence and presence of ASNase.  
C. Flow chart for a genome-wide CRISPR-Cas9 functional screen in PC3 cells.  
D. Volcano plots for the MAGeCK pipeline analysis of the sgRNA abundance from the screen. 
Green dots indicate positive controls and red dots indicate candidates with a fold discovery rate 
(FDR) <0.003.  
E. IncuCyte cell proliferation curves of SLC1A3 knockout (sgSLC1A3) and control (sgNon-targeting) 
PC3 cells in the absence and presence of ASNase treatment. #3 and #4 represent 2 different 
sgRNAs targeting SLC1A3.  
F. Radioactive labeled aspartate and glutamate uptake measurement in control (sgNon-targeting) 
and SLC1A3 knockout (sgSLC1A3) PC3 cells. #3 and #4 represent two different sgRNAs 
targeting SLC1A3. Radioactive labeled leucine uptake was used as a control. Data was 
normalized to the reads of control PC3 cells.  
G. Endogenous levels of aspartate, asparagine, glutamate and glutamine in control (sgNon-targeting) 
and SLC1A3 knockout (sgSLC1A3) PC3 cells with or without ASNase for 3 days. Median peak 
intensity was used for the read normalization.  
H. IncuCyte cell proliferation curves of SLC1A3 knockout (sgSLC1A3#3) PC3 cells treated with 
ASNase and supplemented with either esterified-aspartate (6mM) or esterified-glutamate (6mM), 
and esterified-leucine (6mM) as a control.  
 
Data information:  
For IncuCyte proliferation assays, images were taken every 4 hours and the cell confluence was 
calculated by averaging three mapped images per well. All results were calculated from three replicates 
and presented as mean ± SD, unless otherwise stated. The p-value was calculated by two-tailed unpaired 
t test by Prism7. **p<0.01, ***p<0.001.  
 
SLC1A3 mRNA levels correlate with ASNase sensitivity in different cancer cells 
Because SLC1A3 transports both aspartate and glutamate (Figs 1F and 1G), we mainly further 
used aspartate uptake as a functional readout for SLC1A3. We investigated the correlations 
between SLC1A3 mRNA level, aspartate uptake and sensitivity to ASNase treatment in a panel 
of prostate and breast cancer cell lines. As predicted, we observed a general trend where 
relatively high SLC1A3 mRNA levels indicated high basal aspartate uptake capability (Figs 2A–
 B). The exceptions in our cohort were LNCaP, SUM159PT and BT549 cells, with low SLC1A3 
mRNA level but high basal aspartate uptake capacity. This can be explained by the relatively 
high expression of other aspartate/glutamate transporters in these cells (Fig 2C). Accordingly, 
SLC1A3-KO reduced aspartate uptake level only in SLC1A3-expressing cancer cells (Figs 2A–
B). Interestingly, the sensitivity profiles of the tested cancer cell lines to ASNase treatment were 
generally consistent with the impact of SLC1A3-KO on aspartate uptake, with the exception of 
BT549 cells (Figs 2B and 2D). To further confirm the correlation between aspartate/glutamate 
uptake capacity and ASNase sensitivity, we used SLC1A3-deficient MCF7 cells (breast cancer 
cell line) and DU145 cells (prostate cancer cell line), and established two cancer cell lines 
overexpressing SLC1A3: MCF7-V5-SLC1A3 and DU145-V5-SLC1A3. Figs 2E–G verified 
SLC1A3 ectopic expression, its subcellular localization to the plasma membrane, and its 
capacity to uptake up aspartate in those two cell lines. Importantly, acquired ASNase resistance 
was observed in both cell lines after the ectopic expression of SLC1A3 (Fig 2H). In line with the 
above results, the addition of cell-permeable aspartate and glutamate, but not esterified leucine, 
to DU145 cells, restored cell proliferation under ASNase conditions (Fig 2I). Taken together, we 
conclude that SLC1A3-mediated aspartate/glutamate uptake promoted ASNase resistance. 
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 Figure 2. SLC1A3 expression is linked to ASNase resistance in different cancer cells. 
A. RT-qPCR analysis was used to determine the relative SLC1A3 mRNA expression (to GAPDH) in 
different prostate and breast cancer cell lines, as indicated.  
B. The same cell lines (as in panel A) were transduced with either control (sgNon-targeting) or 
sgSLC1A3. Aspartate uptake levels were determined and compared between control and 
SLC1A3 KO in these cell lines. Leucine uptake level was used for normalization. The numbers 
above the control column denote the basal aspartate uptake capacity.  
C. RT-qPCR was used to determine the relative mRNA levels (to GAPDH) of aspartate/glutamate 
transporter genes (SLC1A1, SLC1A2, SLC1A3, SLC1A6 and SLC1A7) in LNCaP, BT549 and 
SUM159PT cells.  
D. The same batch of cancer cells (as in panel B) was subjected to IncuCyte cell proliferation assays 
in the absence or presence of ASNase at indicated concentrations  ‘ns’ indicates no si nificant 
difference.   
E. MCF7 and DU145 cells were transduced with either lentiviral empty vector (control) or lentiviral 
vector containing a V5-tagged SLC1A3 coding sequence (V5-SLC1A3). Relative SLC1A3 mRNA 
levels (to GAPDH) were determined by RT-qPCR.  
F. Immunofluorescence staining of the V5-tagged SLC1A3 in MCF7 and DU145 cells using anti-V5 
antibody. Green staining indicates the plasma membrane localization of V5-SLC1A3 and blue 
DAPI staining marks the nuclei. Scale bar stands for 5 m. 
G. Relative aspartate uptake levels in control and V5-SLC1A3-expressed MCF7 and DU145 cells. 
Leucine uptake level was used for normalization. 
H. Control and V5-SLC1A3 expressed MCF7 and DU145 cells were subjected to IncuCyte cell 
proliferation assays with or without ASNase at indicated concentrations.  
I. DU145 cells were supplemented with cell-permeable aspartate (6mM, esterified) or glutamate 
(3mM, esterified) following ASNase treatment, with esterified leucine (6mM or 3mM) as control. 
 
Data information: Results were calculated based on three replicates (except for SUM159 and BT549 in B, 
n=2) and presented as mean ± SD. The p-value was calculated by two-tailed unpaired t test in Prism7. 
**p<0.01, ***p<0.001. a.u. indicates arbitrary unit. 
 
Combination of SLC1A3 inhibition and ASNase induces metabolic vulnerabilities that 
impede cancer cell proliferation 
Next, we assessed chemical SLC1A3 inhibition in the context of ASNase. We mainly compared 
two SLC1A3 inhibitors, the selective non-substrate blocker UCPH-101 (Abrahamsen et al, 2013) 
and TFB-TBOA (Shimamoto et al, 2004). By aspartate uptake assay, we observed that the 
inhibitory activity of TFB-TBOA was far more potent than that of UCPH-101, even reaching a 
 nanomolar level (Fig EV2A). Therefore, we used TFB-TBOA for further experiments. Notably, 
while TFB-TBOA and ASNase respectively had either no or mild effect on PC3 cell proliferation, 
their combinational treatment effectively hindered cell proliferation and cell cycle progression 
(Figs 3A–B and EV2B–D). In addition, TFB-TBOA completely restored the adverse effect of 
ASNase in DU145-V5-SLC1A3 cells but had no influence on DU145 wildtype cells (Figs 3A and 
3C). Interestingly, while the combinational treatment impaired cell cycle progression in PC3 
cells, it caused apoptosis in DU145-V5-SLC1A3 cells (Figs 3C and EV2E). 
 
Next, we investigated the effects of combined ASNase and SLC1A3 inhibition on intracellular 
amino acids and key metabolites levels by liquid-chromatography mass spectrometry (LC-MS). 
In concordance with SLC1A3-KO, SLC1A3 inhibition by TFB-TBOA promoted further depletions 
of aspartate and glutamate pools in PC3 cells in the presence of ASNase (Fig 3D). However, in 
contrast to SLC1A3-KO, TFB-  OA didn’t pert rb aspartate,  l tamate and  l tamine le els, 
probably due to the short drug exposure time compared with the genetic manipulation. Notably, 
combined ASNase and SLC1A3 inhibition induced a marked reduction in argininosuccinate from 
the urea cycle (Fig 3E). This effect can be reasoned by the lack of aspartate availability as a 
substrate for argininosuccinate synthesis (Rabinovich et al, 2015). Moreover, nucleotide 
synthesis and tricarboxylic acid (TCA) cycle replenishments were also impaired (Fig 3E), 
probably due to the deficit of aspartate as previously described (Rabinovich et al, 2015; Ahn & 
Metallo, 2015). We also observed that combinational treatment disturbed the NAD+/NADH 
homeostasis, an important indicator for cellular energy assessment and oxidative status (Fig 
3E). And strong lactate depletion was detected, at least partly due to the depletion of NADH (Fig 
3E). Moreover, levels of carnitine metabolites (important transporters for lipid metabolism) was 
also perturbed under combinational conditions (Fig 3E). Above all, in SLC1A3 expressed PC3 
cells, ASNase and TFB-TBOA impact metabolites involved in the urea cycle, nucleotides 
synthesis, energy production by TCA cycle and glycolysis, as well as oxidative homeostasis and 
lipid metabolism. These metabolic alterations further explain why PC3 cells resist ASNase 
treatment but become vulnerable once SLC1A3 is either genetically depleted or chemically 
blocked. 
 
We also probed the key metabolites in DU145 and DU145-V5-SLC1A3 cells. In DU145 cells 
(lacking SLC1A3 expression), ASNase alone was sufficient to induce a similar metabolic profile 
as obtained in PC3 treated with ASNase and SLC1A3 inhibition (Figs EV2F). Ectopic 
 expression of SLC1A3 negated these adverse effects, and accordingly, the addition of TFB-
TBOA restored those perturbations in DU145-V5-SLC1A3 cells (Figs EV2F).  
 
Then we inquired whether ASNase treatment promotes a special usage of cellular 
aspartate/glutamate. For that purpose, we conducted metabolic flux studies using [13C4,15N] L-
aspartate and [13C5,15N] L-glutamate in DU145-V5-SLC1A3 cells. Notably, as observed before 
(Sullivan et al, 2018), exogenous labeled aspartate was barely incorporated to the intracellular 
asparagine pool. Instead, both labeled aspartate and glutamate were actively used to replenish 
downstream metabolisms, such as TCA cycle, urea cycle and nucleotide synthesis. However, 
following ASNase treatment, the relative profiles of labeled metabolites remained generally 
similar to mock treated cells, except for increased incorporation into glutamine from labeled 
glutamate (Fig EV3B–C). Thus, ASNase treatment did not induce significant perturbations in the 
general metabolic usage of aspartate and glutamate in cancer cells. 
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 Figure 3. Combinational treatment of ASNase and SLC1A3 inhibition induced metabolic 
vulnerabilities and restrains cancer cell proliferation. 
A. PC3, DU145 and V5-SLC1A3-DU145 cells were subjected to ASNase and TFB-TBOA treatment 
at indicated concentrations and cell proliferation was measured by IncuCyte assay.  
B. PC3 cells were treated under indicated conditions for 9 days and subjected to BrdU assays to 
determine cell cycle distributions. ASNase (0.3 U/ml), TFB-TBOA (5 M).   
C. DU145 and V5-SLC1A3-DU145 cells were treated under indicated conditions with ASNase (0.2 
U/ml) or TFB-TBOA (20M) or both, and subjected to IncuCyte analysis for apoptotic cell counts.  
D. PC3 cells were treated under ASNase (0.3 U/ml), or TFB-TBOA (5 M) conditions for 3 days and 
cell lysates were extracted and intracellular contents of aspartate, asparagine, glutamate and 
glutamine were determined by liquid-chromatography mass spectrometry (LC-MS).   
E. From the same experiment as in panel D, key metabolites involved in urea cycle, pyrimidine 
synthesis, TCA cycle, oxidation, glycolysis and carnitines metabolism were determined. The 
NAD+/NADH ratio of the indicated conditions was calculated and normalized to control (mean± 
SEM). Dash line indicates indirect effect. TCA cycle: tricarboxylic acid cycle; OAA: oxaloacetic 
acid; UMP: uridine monophosphate; CMP: cytidine monophosphate; PEP: phosphoenolpyruvate; 
NADH: nicotinamide adenine dinucleotide (reduced form); NAD+: nicotinamide adenine 
dinucleotide (oxidized form); NADPH: nicotinamide adenine dinucleotide phosphate (reduced 
form); NADP+: nicotinamide adenine dinucleotide phosphate (oxidized form); FAD: flavin adenine 
dinucleotide; GSSG: glutathione disulfide; HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA. 
 
Data information: Median peak intensity was used for raw data normalization in (D and E). Results were 
calculated based on three replicates and presented as mean ± SD (unless otherwise stated). The p-value 
was calculated by two-tailed unpaired t test from Prism7. *p<0.05, **p<0.01, ***p<0.001.  
 
Gene expression analysis indicates the novel role of SLC1A3 in ASNase resistance 
To interrogate the influence on differential gene expression profiles by SLC1A3 and ASNase, 
we performed transcriptome analysis in three cancer cell lines: PC3 (endogenous expression of 
SLC1A3), DU145 wildtype (SLC1A3 negative) and DU145-V5-SLC1A3 (ectopic expression of 
SLC1A3). Consistent with the compromised cell cycle progression in PC3 cells (Figs 3B and 
EV2B–D), genes related to cell cycle progression were inhibited following ASNase and TFB-
TBOA combinational treatment (Fig 4A). ASNase-treated DU145 cells presented upregulated 
apoptotic signatures, corresponding to the apoptosis phenotype observed in these cells 
following ASNase treatment (Figs 4B and 3C). Intriguingly, the introduction of SLC1A3 to 
DU145 cells prevented the emergence of the apoptosis signature, which was restored by the 
addition of TFB-TBOA (Figs 4C and 3B). The molecular pathways related to lipid metabolism, 
 for example, the biosynthesis of cholesterol, steroid and mevalonate, and the gene expression 
related to sterol regulatory element-binding protein (SREBP), have been strongly impaired in all 
three cancer cell lines when SLC1A3 was either chemically blocked or intrinsically absent 
following ASNase treatment (Figs 4A–C).  
 
More specifically, we observed increased VEGFA mRNA levels after combinational treatment in 
PC3 cells (Fig EV4A), in line with previous observations that suggested a negative correlation 
between VEGFA and aspartate level (Garcia-Bermudez et al, 2018). Moreover, the decreased 
mRNA level of lactate dehydrogenase A (LHDA) can explain the depletion in lactate level 
measured by metabolites profiling (Fig 3E). Though ASNS mRNA level was strongly 
upregulated by ASNase and SLC1A3 inhibition in DU145-V5-SLC1A3 cells, still, cell death was 
induced (Fig EV4C). This indicates that elevated asparagine synthesis by ASNS could be 
insufficient to convey ASNase resistance, which might also be determined by 
aspartate/glutamate bioavailability.  
 
Altogether, we conclude that the transcriptomic changes (Figs 4A–C) are in concordance with 
metabolomic perturbations (Figs 3E and EV2F) and cellular outcomes (Figs 3A–C), indicating a 
novel role of SLC1A3 in cancer cell survival following ASNase treatment. 
  
  
    
 
   
 
      
 holesterol bios nthesis
Steroid  ios nthesis
Acti ation of  ene e pression b  S      S     
me alonate pathwa 
 pre  lated pathwa s in ASNase and ASNase       OA treated       cells
 ownre  lated pathwa s in ASNase and ASNase       OA treated       cells
      
 holesterol bios nthesis
Steroid  ios nthesis
Acti ation of  ene e pression b  S      S     
me alonate pathwa 
Sal a e p rimidine deo  ribon cleotides
 
    
t pe   interferon si nalin  pathwa 
apoptotic process
response to  nfolded protein
response to star ation
 
 lo   p  al e 
  
 lo   p  al e 
  
 lo   p  al e 
  
    
apoptotic process
cell lar response to n trient le els
response to endoplasmic retic l m stress
 lo   p  al e 
  
 pre  lated O biolo ical process in ASNase       OA treated          S   A  cells
 ownre  lated pathwa s in ASNase       OA treated          S   A  cells
        
 holesterol bios nthesis
Steroid  ios nthesis
Acti ation of  ene e pression b  S      S     
 NA  eplication
 ell   cle
 lo   p  al e 
  
     
 enes encodin  secreted sol ble factors
Senescence Associated Secretor   henot pe  SAS  
 irect p   e ffectors
A     transcription factor networ 
 nfolded  rotein  esponse      
 lo   p  al e 
  
 pre  lated pathwa s in ASNase       OA treated     cells
 ownre  lated pathwa s in ASNase       OA treated     cells
A
     
         S   A 
  
    
 
   
 
 oc       OA
     
ASNase
      ml 
ASNase      ml 
       OA    
 oc       OA
     
ASNase
      ml 
ASNase      ml 
       OA     
  
    
 
   
 
   
 oc       OA
     
ASNase
      ml 
ASNase      ml 
       OA    
 Figure 4. Gene expression changes pinpoint key pathways involved in SLC1A3-mediated 
ASNase resistance. 
A–C. PC3 (A), DU145 (B) and DU145-V5-SLC1A3 (C) cells were treated with ASNase (0.3 U/ml in A; 
0.2 U/ml in B and C), TFB-TBOA (5 M) for 3 days as indicated and subjected to transcriptome 
analysis. Bioinformatics pathway or gene ontology (GO) biological process analysis was performed on 
the sets of genes that were upregulated or downregulated when PC3 cells were treated with ASNase 
and TFB-TBOA compared to mock. Transcriptome analysis was based on one biological replicate for 
each cell line and validated by real-time PCR experiments in Figures EV4A–C. Heatmap presents row 
scaled normalized read counts and the biological signaling pathway enrichment analysis was performed 
by ToppGene online program (Chen et al, 2009). 
 
SLC1A3 expression promotes tumor progression and ASNase resistance in a mouse 
model for breast cancer metastasis 
Next, we set up experiments to examine the role of SLC1A3 in tumor response to ASNase 
treatment in vivo. As a first step, we interrogated the impact of ASNase treatment on asparagine 
and glutamine levels in mice with human breast cancer xenografts. We orthotopically injected 
human breast cancer cells (SUM159PT) to mammary fat pads of NOD-Scid IL2Rg-null (NSG) 
mice, allowed tumors to develop to ~250 mm3 and then systemically injected 60U ASNase per 
day for 5 consecutive days. Remarkably, we detected very strong ASNase-induced depletions 
of asparagine not only in the blood, but also in the mammary fat pad tissues and even within the 
growing tumors (Fig 5A). However, unlike the glutaminase effect of ASNase in vitro, here we 
detected very modest perturbation in glutamine levels (Fig EV5A). This is probably due to the 
instant glutamine replenishment under in vivo conditions. ASNase treatment could potentially 
disturb tumor growing environment, at least in the perspective of asparagine.  
 
Next, we employed 4T1, a highly malignant mouse breast cancer cell line, for the assessment of 
the influence of SLC1A3 on ASNase efficacy in vivo. This cell line does not express SLC1A3 
(www.biogps.org), does not take up aspartate, and accordingly shows high sensitivity to 
ASNase treatment (Fig EV5B). As expected, ectopic expression of SLC1A3 (4T1-V5-SLC1A3) 
promoted exogenous aspartate uptake and restored 4T1 proliferation in the presence of 
ASNase in vitro (Fig EV5B). We therefore implanted 4T1 and 4T1-V5-SLC1A3 cells into the 
mammary fat pad of either mock or ASNase pretreated NSG mice and measured tumor 
development. Intriguingly, while the growth of tumors derived from parental 4T1 cells was 
impaired by ASNase at an early stage (day 9 and 12), SLC1A3-expressing tumors showed no 
significant differences between ASNase- and mock-treatment (Figs 5B and EV5C). Moreover, 
 consistent with recent reports (Sullivan et al, 2018; Garcia-Bermudez et al, 2018), implantation 
of SLC1A3-expressing 4T1 cells resulted in relatively faster tumor growth compared to that of 
parental 4T1 cells (Fig EV5D). Once tumors reached the volume of ~500mm3, mastectomy was 
performed to remove the primary tumors. The amino acids analysis of the harvested tumor 
samples by mass spectrometry revealed almost complete depletion of asparagine by ASNase, 
regardless of SLC1A3 expression status, and slightly reduced aspartate levels in parental 4T1 
cells derived tumors following ASNase treatment (Fig 5C). Intriguingly, we also observed 
depleted glutamine and glutamate levels in control tumors (Fig 5C). This might relate to the 
absence of SLC1A3 or other aspartate/glutamate transporters in 4T1 cells, which might 
decelerate glutamine replenishment in the presence of ASNase, at least in this model. Of note, 
the introduction of SLC1A3 into 4T1 cells (4T1-V5-SLC1A3) increased intratumor aspartate and 
glutamate levels, and further negated aspartate and glutamine depletions by ASNase treatment 
at the cost of glutamate consumption (Fig 5C). 
 
Following mastectomy, mice survival rate was scored. In agreement with the effect of ASNase 
on primary tumor establishment, mice bearing tumors derived from parental 4T1 cells survived 
better early after ASNase treatment than mock treated mice (Fig EV5E, left). In contrast, 
ASNase treatment had no effect on the survival rate of mice with SLC1A3-expressing tumors, 
even at early stage (Fig EV5E, right). 
 
Recently, the bioavailability of asparagine was reported to govern breast cancer metastasis, and 
ASNase could reduce breast cancer metastasis (Knott et al, 2018). From our results above, 
SLC1A3 mediated aspartate/glutamate imports could affect ASNase treatment. Therefore, we 
next assessed whether SLC1A3 expression could negate the inhibitory effect of ASNase on 
cancer cell invasion in a mouse metastasis model for human breast cancer cells as described 
recently (Knott et al, 2018). For this purpose, we used MDA-MB-231 human breast cancer cells 
whose metastasis burden was reduced by ASNase (Knott et al, 2018). Similar to 4T1 cells, 
MDA-MB-231 cells hardly expressed SLC1A3 (Fig 2A), did not take up aspartate and were 
highly sensitive to ASNase (Fig EV5F). Consistent with above results (Figs 2G–H), SLC1A3 
expression increased aspartate uptake and promoted MDA-MB-231 cell proliferation in the 
presence of ASNase (Fig EV5F). We therefore introduced MDA-MB-231 and MDA-MB-231-V5-
SLC1A3 cells intravenously into NSG mice and assessed the invasive burdens in lung and liver. 
As previously reported (Knott et al, 2018), ASNase treatment reduced metastasis of parental 
MDA-MB-231 cells to the lung (Fig 5D). In contrast, the introduction of SLC1A3 increased 
 metastatic burdens and overcame the inhibitory effect by ASNase (Fig 5D). Thus, we conclude 
that SLC1A3 expression induces tumor progression and ASNase resistance. 
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 Figure 5. SLC1A3 expression promotes ASNase resistance and tumor progression in a 
mice model for breast cancer metastasis.  
A. SUM159PT human breast cancer cells were orthotopically injected into the mammary glands of 
NSG mice. Once SUM159PT tumors reached 250mm3 volume, mice were treated with mock or 
ASNase (60U per day) for 5 consecutive days (n=3). Following treatment, mice were sacrificed, 
and blood, mammary glands and tumors were collected and subjected to mass spectrometry to 
determine the asparagine level. Essential amino acids were used for the raw data normalization. 
Data are presented as mean ± SD. 
B. The mouse breast cancer cell lines 4T1 and 4T1-V5-SLC1A3 were orthotopically implanted into 
the mammary glands of pretreated NSG mice. Presented is the volume measurements of arising 
tumors at day 9. (n=13 mice for each group, except for 4T1+ASNase, n=12). Data are presented 
as mean ± SEM.  
C. From the same experiment in panel B, tumors were surgically removed once reached a volume of 
~500mm3 and collected and subjected to LC-MS to determine the levels of asparagine, aspartate, 
glutamine and glutamate. Leucine level was used as a control. Results are based on five tumor 
samples and presented as mean ± SEM. 
D. The human breast cancer cell lines MDA-MB-231 and MDA-MB-231-V5-SLC1A3 cells were 
intravenously injected into pretreated NSG mice. Once mice showed breathing problems, they 
were sacrificed, and lung and liver were collected and blindly scored for metastasis lesions. The 
p-value was calculated by one-tailed unpaired t test in Prism7. Data are presented as mean ± 
SEM (n=8). 
E. A schematic model depicting how SLC1A3-mediated aspartate and glutamate uptake promotes 
ASNase resistance.  
 
Data information: The pretreatment started 2 days before the injection of cancer cells. And mice were 
either injected with 60 U ASNase or saline per day. The p-value was calculated by two-tailed unpaired t 
test in Prism7, unless otherwise stated. *p<0.05, **p<0.01, ***p<0.001. 
 
 
  
 Discussion  
 
Although asparagine deprivation by ASNase was discovered as an effective treatment in 
lymphomas approximately 5 decades ago, its clinical implementation to other tumor types failed 
(Clarkson et al, 1970; Pui et al, 2009; Hays et al, 2013). The resistant mechanism to ASNase 
treatment in solid tumors was mainly attributed to the activation of the general amino acid 
sensing machinery (GCN2) and asparagine synthesis by ASNS via the GCN2-ATF4-ASNS axis 
(Scherf et al, 2000; Ye et al, 2010; Bunpo et al, 2009; Nakamura et al, 2018). However, the 
e pression of ASNS in A   didn’t compromise ASNase effecti it  (Vander Heiden & 
DeBerardinis, 2017), indicating that the ubiquitous activation of the GCN2-ATF4-ASNS axis in 
response to nutrient deprivation might be essential, but not sufficient to induce ASNase 
resistance. Very recently, protein degradation was proposed to contribute to ASNase resistance 
in ALL (Hinze et al, 2019), however, its contribution in the context of solid tumors is not known 
yet. Here, we described the identification of SLC1A3, an aspartate/glutamate transporter, as a 
novel contributor to ASNase resistance and metastasis in cancer cells. As SLC1A3 is 
specifically expressed in brain tissues, this expression pattern may be beneficial to guide 
ASNase treatment in solid tumors. 
 
ASNase could break down both asparagine and glutamine, even though its glutaminase activity 
was not required for ASNS-negative cancer cells (Chan et al, 2014). Moreover, ASNase was 
found effective in treating solid tumors with intrinsic loss of ASNS (Li et al, 2019). We observed 
that in cell culture conditions, both asparagine and glutamine were robustly depleted by ASNase 
(Fig 1G). However, in vivo conditions, asparagine was far more effectively depleted than 
glutamine (Figs 5C and EV5A), probably due to the abundant bioavailability and timely 
replenishment of glutamine that reduced the effect of glutaminase activity of ASNase. The 
importance of asparagine to tumor cell survival was further highlighted in recent studies. Ye at 
al., has demonstrated the importance of asparagine synthesis via GCN2-ATF4 axis for tumor 
cell survival during nutrient deprivation (Ye et al, 2010). And it has been demonstrated the 
essential role of asparagine in promoting cancer cell proliferation and breast cancer metastasis 
(Krall et al, 2016; Pavlova et al, 2018; Knott et al, 2018). Altogether, our study provides another 
support for the role of asparagine in cancer biology, and puts forward the potential usage of 
ASNase in cancer therapy. 
 
 According to a previous study, aspartate metabolism was predicted to contribute to ASNase 
resistance in primary ALL samples (Chen et al, 2011). Our results that ASNase resistance could 
be provoked by either ectopic SLC1A3 expression or the supplementation of membrane 
permeable aspartate/glutamate strongly support this hypothesis (Figs 1H and 2H–I). It indicates 
that SLC1A3-mediated fueling of endogenous aspartate/glutamate levels is a novel contributor 
to ASNase resistance. Moreover, aspartate was the second most enriched amino acid (after 
asparagine) for genes related to epithelial-to-mesenchymal transition (Knott et al, 2018). In line 
with this, we observed that SLC1A3 expression could promote cancer cell metastasis, 
regardless of asparagine bioavailability (Figs 5D and EV5E). Even though recent studies mainly 
focused on SLC1A3-mediated aspartate uptake (Alkan et al, 2018; Garcia-Bermudez et al, 
2018; Sullivan et al, 2018; Tajan et al, 2018), we could not exclude the role of glutamate, which 
could be converted to aspartate via oxidative or reductive carboxylation. This is supported by 
our findings that both aspartate and glutamate could rescue ASNase toxicity in SLC1A3 KO or 
negative cancer cells (Figs 1H and 2I).  
 
Notably, we demonstrate that SLC1A3 inhibition in combination with ASNase treatment could 
hinder cancer cell proliferation by inducing either cell cycle arrest or apoptosis, which was 
observed in ALL cells following ASNase treatment (Kidd, 1953; Broome, 1961; Pui et al, 2009; 
Ueno et al, 1997). Metabolic and transcriptomic profiles of cells treated with ASNase and 
SLC1A3 inhibition indicated numerous defects in many critical processes (Figs 3E and EV2F). 
Intriguingly, in addition to the well-known engagements in urea cycle, nucleotide synthesis and 
TCA cycle replenishments (Van Vranken & Rutter, 2015; Rabinovich et al, 2015; Sullivan et al, 
2015), aspartate and glutamate metabolisms might also directly or indirectly influence energy 
production, oxidation homeostasis and lipid metabolism following ASNase treatment (Fig 5E).  
 
O r metabolomic and “diricore” anal ses indicated that ASNase-treated SLC1A3-expressing 
cancer cells and tumors still present asparagine shortage (Figs 5A and 5C) (Loayza-Puch et al, 
2016). Consistent with a previous study (Sullivan et al, 2018), our metabolic flux assays 
demonstrated that asparagine pool was not efficiently replenished by labeled aspartate (Fig 
EV3A). In mammalian cells, the lack of asparaginase activity prohibits asparagine utilization for 
the production of other amino acids or for the biosynthesis of metabolic intermediates (Pavlova 
et al, 2018). Thus, intracellular asparagine seems to be mostly consumed for protein synthesis, 
and the cells seem to be dependent on exogenous asparagine.  
  
Homologues of SLC1A3 (SLC1A1, SLC1A2, SLC1A6 and SLC1A7) can also transport  
aspartate/glutamate (Kanai et al, 2013). It remains to be further investigated whether these 
transporters also contribute to ASNase resistance in some cancer cells. The compound TFB-
TBOA could potently inhibited SLC1A3, which leads to the negation of SLC1A3 in ASNase 
resistance in vitro. However, in vivo tests with TFB-TBOA showed poor pharmacokinetics 
activity (a sharp drop in serum levels 7 hours post injection, data not shown). Future 
pharmacological manipulation of TFB-TBA might be needed to improve its in vivo performance. 
 
Altogether, using a genome-wide functional genetic approach, we identified SLC1A3, an 
aspartate/glutamate transporter, as a key determinant in the survival of cancer cells during 
ASNase treatment. We pinpointed the role of aspartate/glutamate in fueling metabolic pathways 
related to urea cycle, nucleotide, energy production, oxidation homeostasis, lipid metabolism, 
and glutamine biosynthesis, in this process. Our results show that solid tumors are amendable 
to systemic administration of ASNase, opening the possibility of expanding ASNase benefit to 
solid tumors.  
 
 
 
 
 
  
 Materials and Methods: 
Cell culture 
The human prostate cancer cell lines (PC3, DU145, LNCaP and 22RV1) were bought from 
ATCC and cultured in RPMI (Thermo Fisher Scientific). The human breast cancer cell lines 
(MCF7, MDA-MB-231 and MDA-MB-468) were cultured in high glucose DMEM. SUM159PT 
cells (archived in the lab) were cultured in DMEM/F12 1:1 medium with addition of insulin 
(sigma, I1882-100MG, final concentration of 5 g/ml) and hydrocortisone (sigma, final 
concentration of 1 g/ml). BT549 cells (archived in the lab) were cultured in RPMI with insulin 
(final concentration of 5 g/ml). The mouse breast cancer cell line 4T1 was a gift from O. v. 
Tellingen (Amsterdam, the Netherlands), and cultured in DMEM (high glucose). HEK-293T 
packaging cell line for lentivirus production were cultured in high glucose DMEM. All the 
mediums were supplemented with 10% FBS, 1% penicillin/streptomycin except for SUM159PT 
cells (5% FBS + 1% penicillin/streptomycin). All the cells were cultured in a humidified 37°C 
incubator with 5% CO2 injection. 
IncuCyte cell proliferation assay 
Cells were seeded in 96-well plate (Greiner, 655090) and 3 images per well were taken every 4 
hours by the IncuCyte imaging system (Essen Bioscience). Cell confluence per well was 
calculated by averaging the mapped areas for those 3 images. Experiments were performed 
with independent triplicates. 
Generation of SLC1A3 expression plasmid 
SLC1A3 cDNA was amplified from the pLX304-SLC1A3 plasmid kindly gifted by Roderick 
Beijersbergen (Amsterdam, the Netherlands) using the following primer sequences:  
 ’-ACAGCGTCTAGACCGGTTAGCGCTAGCTCATTAC- ’ and  
 ’-CGACAGTTAGCCAGAGAGCTCGCGGCCGCCGCTGT- ’   he res ltin  prod ct was 
digested using XbaI (Roche) and NotI (Thermo Fisher Scientific) restriction enzymes and ligated 
into a pLenti backbone (Korkmaz et al, 2016) with compatible sticky ends. 
Lentivirus production and infection 
A third-generation lentivirus packaging system consisting of pCMV-VSV-G (Addgene#8454), 
pRSV-Rev (Addgene #12253) and pMDLg/pRRE (Addgene #12252) was co-transfected with 
lentiCRISPR v2 (addgene: #52961) containing sgRNA. Transfection was performed in HEK-
293T cells using PEI (polyethylenimine, Polysciences) and medium was refreshed after 18 
 hours. Virus was harvested 48 hours after transfection by snap-frozen and stored at -80°C. 
Target cells were incubated with virus for 24 hours and then medium was refreshed. 36 hours 
after virus infection, target cells were selected with either puromycin (1 g/ml) or blasticidine (5 
g/ml) according to the need of the experiments. The selection stopped when no surviving cells 
remained in the no-transduction control plate and cells were switched to normal culture medium. 
CRISPR-Cas9 genome-wide screen in PC3 cells and MAGeCK analysis 
PC3 cells were transduced with lentivirus pools containing sgRNAs of a genome-wide CRISPR-
Cas9 Brunello library (Doench et al, 2016) (addgene #73179) at a multiplicity of infection (moi) 
of ~ 0.3 and ~1000× representations for each guide  After  ~  da s’ reco er  from p rom cin    
g/ml) selection, cells were split into two different conditions: one was subjected to ASNase 
treatment (0.3 U/ml, ITK) for 20 days, and the other to mock treatment. Two independently 
replicates were included. Subsequently, genomic DNA was isolated using the phenol-chloroform 
extraction protocol and sgRNAs were amplified using a two-step PCR protocol for next-
generation sequencing. Libraries were sequenced in an Illumina HiSeq-2500 sequencer and 
raw reads were demultiplexed and analyzed using the in-house perl script XCALIBR 
(https://github.com/NKI-GCF/xcalibr). The individual sgRNAs abundance were further analyzed 
using MAGeCK (Li et al, 2014) pipeline to find genes statistically depleted during the screening. 
The MAGeCK software was ran with default options and the 1000 non-targeting sgRNAs 
included in the CRISPR-Cas9 library were used for control normalization. 
 ist     forward primer:  ’- ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT NNN 
NNN GGC TTT ATA TAT CTT GTG GAA AGG ACG - ’ and first     re erse primer:  ’- GTG 
ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC TAC TGA CGG GCA CCG GAG CCA ATT 
CC - ’   he forward primer contained a barcode  NNNNNN  that enabled m ltiple ing. 
Second     forward primer:  ’- AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC 
CTA CAC GAC GCT CTT CCG ATC T - ’ and re erse primer:  ’- CAA GCA GAA GAC GGC 
ATA CGA GAT CGA TGT GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC T - ’  
Competitive cell proliferation assay 
PC3 parental cells were stably transfected with pLKO-H2B-GFP and mixed with plentiv2-sgRNA 
transfected PC3 cells (GFP-negative) at a ratio of ~3:7 and seeded into 12-well plates in the 
absence or presence of ASNase (0.3 U/ml). Cells were split every 3~5 days and the ratio of 
GFP-negative cells among the mixed population was measured by flow cytometry (Calibur, BD 
 Biosciences). GFP-negative cell counts at each timepoint were normalized to day 0 when the 
cells were initially mixed. 
Radioactive aspartate uptake assay 
Cells were counted and seeded one day before the assay in 12-well plates as described 
(Loayza‐Puch et al, 2017). After washed twice with PBS, cells were incubated respectively with 
[3H] L-leucine (in sodium-free uptake buffer) and [3H] L-aspartate (in PBS) for 5 minutes. Next, 
cells were washed twice with ice-cold PBS and collected with 0.1 M NaOH. The counts for 
radioactivity was measured by a liquid scintillation analyzer on LSC2910 PerkinElmer Counter. 
Leucine uptake was used for normalization. 
BrdU labeling 
For PC3 cells, a final concentration of 10 M bromodeoxyuridine (BrdU, Sigma) was added to 
the medium and incubated for 25 mins. Cells were harvested and fixed with 70% cold ethanol at 
4°C for 30 minutes. RNase A treatment (final concentration at 0.5 mg/mL) at 37°C for 30 mins 
was applied. Cells were resuspended in freshly prepared HCl/0.5% Triton solution (for DNA 
denature) at room temperature for 20 minutes and then neutralized by 0.1 M Na2B4O7. After 
washed once with PBS/Tween, cells were incubated with 1:40 diluted anti-BrdU antibody (Dako) 
at RT for 30 mins. Cells were incubated with FITC-conjugated anti-mouse Alexa Fluor 488 
secondary antibody (1:500, Dako) at RT for 30 mins in the dark. After washing another 2X, cells 
were then resuspended in PI (20 g/mL) solution and ready for FACS assay (at least 10,000 
cells were gated for each condition). 
Metabolite profiling and isotope tracing 
1.5 × 105 cells were seeded in 6-well plates and treated for 72 hours as indicated. After washed 
twice with cold PBS, cells were subjected to 1 ml lysis buffer composed of 
methanol/acetonitrile/H2O (2:2:1) for metabolites extractions. The lysates were collected and 
centrifuged at 16, 000 g (4°C) for 15 minutes and the supernatant was transferred to a new tube 
for further liquid-chromatography mass spectrometry (LC-MS) analysis. The LC-MS analysis 
procedure and parameters were used as described before (Loayza‐Puch et al, 2017). 
Metabolites were identified and quantified using LCquan software (Thermo Scientific) on the 
basis of exact mass within 5 ppm and further validated by concordance with retention times of 
standards. Peak intensities were normalized based on median peak intensity of total 
metabolites or on essential amino acids. For Fig 5A, 10 l of serum was diluted in 1 ml lysis 
buffer. For Figs 5A and 5C, 50~100 mg mammary fat pad tissues and tumors were ground in a 
 mortar under liquid nitrogen, metabolites were extracted by adding 500 l lysis buffer and 
sonicated for 10 mins before centrifugation. 
For isotope tracing experiment, 2.5 × 105 DU145-V5-SLC1A3 cells were seeded in 6-well plates. 
Next day, cells were exposed to either mock or ASNase (0.2 U/ml) for 48 hours, and then 
supplemented with either 1.5 mM [13C4,15N] L-aspartate (Cambridge Isotope Laboratories, 
CNLM-544-H) and 1.5 mM unlabeled glutamate (Sigma, G8415) or 1.5 mM [13C5,15N] L-
glutamate (Cambridge Isotope Laboratories, CNLM-544-H) and 1.5 mM unlabeled aspartate 
(Bioconnect 47203.01) for 8 hours. Then the cells and the medium were harvested for further 
analysis as described above.  
Total RNA isolation 
Total RNA was isolated  sin   ris re rea ent   ioline  followin  the man fact rer’s instr ctions  
Briefly, cells were washed twice with PBS and 1 ml Trisure was added for homogenization. After 
centrifuge, the aqueous phase was transferred to a new tube and mixed with cold isopropyl 
alcohol for RNA precipitation by centrifuging at 4 °C for 1 hour. RNA pellet was washed twice 
with 75% ethanol and finally dissolved in RNase-free water. 
Reverse-transcription and quantitative real-time PCR (RT-qPCR) 
Reverse transcription was performed with Tetro Reverse Transcriptase kit (Bioline) according to 
the man fact rer’s instr ctions   riefl ,   g total RNA was used as templates for each reaction. 
qPCR reactions were prepared using a SensiFAST SYBR No-ROX kit (Bioline) according to the 
instructions and performed in the Light Cycler 480 (Roche). Primers were listed in Table EV1. 
Western blot analysis 
Cells were washed twice with PBS and lysed with 2× SDS buffer (4% SDS, 20% glycerol and 
125 mM Tris PH 6.8).  Next, protein levels were quantified by Pierce BCA protein assay kit 
(Thermo Scientific). Lysates were loaded into a separating 7.5% SDS-PAGE gel and protein 
was transferred to nitrocellulose membranes. After blocking with 5% milk/PBS-Tween-20 (0.2%) 
solution, the membrane was incubated with mouse-anti-V5 (Thermo Fisher Scientific). Proteins 
were visualized using the secondary fluorescence-labeled antibodies goat-anti-mouse IRDye 
680 RD (LI-COR Biosciences) and scanned on the Odyssey infrared imaging system (LI-COR 
Biosciences). 
Immunofluorescence assay 
 Cells were grown on glass cover slips, washed twice with PBS and fixed with 2% PFA for 10 
minutes at room temperature. Next, cells were permeabilized with 0.5% Triton/PBS solution, 
blocked with 5% FBS for 1 hour and incubated with mouse-anti-V5 (Thermo Fisher Scientific) 
and Alexa-488-conjugated Rabbit anti mouse secondary antibodies. Cover slips were mounted 
on glass slides using Vectashield containing DAPI. Images were taken with Leica confocal 
microscope SP5. 
TruSeq standard mRNA sample preparation 
Stranded-specific libraries were generated using the TruSeq Stranded mRNA sample 
preparation  it   ll mina  followin  the man fact rer’s instr ctions   riefl ,   g of total RNA was 
polyA-selected using oligo-dT beads and the RNA was fragmented, random primed and reverse 
transcribed using SuperScript II Reverse Transcriptase kit (Invitrogen). Second strand 
complementar   NA was then s nthesi ed,  ’-adenylated and ligated to Illumina sequencing 
adapters, and subsequently amplified by 12 cycles of PCR. The sequencing libraries were 
analyzed on a 2100 Bioanalyzer using a 7500 chip (Agilent) and pooled equimolarly into a 30 
nM multiplex sequencing pool. 
Deep sequencing 
Samples were sequenced on the Illumina HiSeq2500 sequencer generating 65-nuclotide single-
end reads.  
RNA-seq analysis 
Sequenced reads were aligned to the human genome (hg19) using TopHat v2.0.8 (Trapnell et 
al, 2009). Only uniquely mapped reads were retained for further analysis. SAMTOOLS v0.1.19 
(Li et al, 2009) was used to convert the BAM output to SAM format and to sort the BAM file. The 
read counts per gene were calculated using the HTSeq program, v0.5.4p1 (Anders et al, 2015). 
The DESeq package (Oshlack et al, 2010) was used to generate normalized read counts and 
for differential gene expression analysis. DESeq called differentially expressed genes with FDR 
cutoff of 0.05 and abs (FC) >1.5 were considered as significant differentially expressed genes. 
IncuCyte® Caspase-3/7 Green apoptosis assay 
Cells were pre-seeded in 96-well plate (Greiner, 655090) 48 hours before the addition of 
Caspase-3/7 Green Apoptosis reagent (Essen Bioscience, 4440). The green signals were 
captured every 4 hours and apoptotic cells were counted. 
Animal studies 
 All mice experiments were approved by the Netherlands Cancer Institute Animal Experimental 
Committee. For Fig EV1E, xenografts were induced by subcutaneous injection of 4 × 106 PC3 
control (sgNon-targeting) and sgSLC1A3 cells (monoclonal #4-1) in one flank of Balb/c nude 
mice (n=8) and treatment started when tumors reached 50 mm3. For Fig 5A, 4 × 106 SUM159PT 
cells were resuspended in 50 l PBS and injected into the mammary gland #4 of NOD-SCID 
IL2R-null (jax) (NSG) mice. After tumor volumes reached ~250 mm3, mice (n=3 per group) were 
administrated either with mock (saline) or ASNase (60 U per day) for 5 consecutive days by 
intraperitoneal injections. Serum, mammary fat pad tissues and tumors were collected and 
snap-frozen for LC-MS analysis when the mice were sacrificed. For Fig 5B, 1 × 105 4T1 cells 
and 4T1-V5-SLC1A3 cells were respectively resuspended in 20 l 1:1 mix of PBS and growth 
factor reduced Matrigel (GeltrexTM, Gibco) and injected into 1 mammary fat pad per mouse. 
Mice were pre-treated for 2 days either with saline or ASNase (60 U per day) before tumor cells 
were introduced and the treatment was performed every day until the mice were sacrificed 
(n=13 per group except for the group of 4T1 treated with ASNase, n=12). Primary tumors were 
surgically removed once the tumor volumes reached 450–550 mm3, and mice underwent 
breathing challenges every day. For Fig 5D, 5 × 104 MDA-MB-231 and MDA-MB-231-V5-
SLC1A3 cells (in 50 l PBS) were respectively injected into the tail veins of 2 da s’ pre-treated 
NSG mice (n=8 per group) and mice were sacrificed 22 days post tumor cells introduction. 
All the experiments were using 6~8 weeks old NSG mice (except for Fig EV1E) and mice were 
weighed every 2 or 3 days to monitor weight loss. For ASNase treatment, mice were 
intraperitoneally administrated 60 U ASNase every day till the end of the experiments. Tumor 
volumes were calculated by the formula V = 1/2(LW2), where L is length and W is width of the 
primary tumor. 
Histopathology analysis of lung and liver invasion 
Lung and liver tissues were collected and fixed in formalin fixative and embedded in paraffin. 
The immunohistochemistry (IHC) of vimentin (DAKO, M0725, dilution: 1:4000) was conducted 
on 4µm-thick sections according to standard procedures. The stained slides were examined 
blindly by a pathologist and the number of tumorous lesions (more than 10 cancer cells) were 
scored in each of the sections. The sections were reviewed with a Zeiss Axioskop2 Plus 
microscope (Carl Zeiss Microscopy, Jena, Germany) and images were captured with a Zeiss 
AxioCam HRc digital camera and processed with AxioVision 4 software (both from Carl Zeiss 
Vision, München, Germany). 
Statistics  
 Data analyses were performed using GraphPad Prism (version 7). The statistical tests used are 
described in figure legends. *p<0.05, **p<0.01, ***p<0.001. For the mass spectrometry analysis 
of amino acids in tumor samples, no statistics methods were used to predetermine sample size. 
For animal experiments, an estimate was made for the number of mice needed, without power 
calculation.  
TCGA datasets analysis 
Expression data from tumor and normal tissue samples were downloaded for every project 
available at ICGC data portal (http://dcc.icgc.org; release 27). For consistency, only expression 
data from pipeline “ NASe   _ S  _ enes” were considered   he downloaded normali ed 
expression data were scaled to TPM (transcripts per million reads) and log2 transformed. Only 
projects with more than 10 normal samples were considered. All analyses were done using R-
language. The statistical comparison between normal and tumor samples was done using a 
Wilcoxon sum rank test with Bonferroni correction for multiple comparisons.  
Data availability 
The deep sequencing datasets generated in this study have been deposited in GEO database 
under accession number: GSE134074. All other data generated that support the findings of this 
study are available from the corresponding author upon reasonable request. 
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 Figure EV1. Validation of hits from the genome-wide CRISPR-Cas9 screen in PC3 cells.  
A. PC3 cells were transduced with individual sgRNA lentiviral vectors as indicated and subjected to 
competitive cell proliferation assays under mock or ASNase (0.3 U/ml) conditions. #1, #3 and #4 
represent different sgRNAs and n=2 for each condition. 
B. PC3 cells were transduced with control (sgNon-targeting) or sgSLC1A3 and subjected to 
IncuCyte cell proliferation assays with or without ASNase (0.3 U/ml). #1 indicates a sgRNA 
targeting SLC1A3 and n=3 for each condition 
C. SLC1A3 expression analysis in normal tissues from GTEX portal 
(gtexportal.org/home/gene/SLC1A3). Red columns indicate high SLC1A3 expression in most 
brain tissues. Expression values are shown in TPM (transcripts Per Million), calculated from a 
gene model with isoforms collapsed to a single gene. No other normalization steps have been 
applied. Box plots are shown as median and 25th and 75th percentiles; points are displayed as 
outliers if they are above or below 1.5 times the interquartile range.  
D. TCGA tumor database analysis of SLC1A3 expression in healthy tissues and primary tumors for 
kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver 
hepatocellular carcinoma (LIHC) and stomach adenocarcinoma (STAD). Expression data from 
tumor and normal tissue samples were downloaded fro every project available at ICGC data 
portal (http://dcc.icgc.org; release 27). For consistency, only expression data from pipeline 
“ NASe   _ S  _ enes” were considered   he downloaded normali ed e pression data were 
scaled to TPM (transcripts per million reads) and log2 transformed. Only projects with more than 
10 normal samples were considered (each dot represents one sample). All analyses were done 
using R-language. The statistical comparison between normal and tumor samples was done 
using a non-parametric Wilcoxon sum rank test followed by Bonferroni correction. Box plots are 
shown as median and 25th and 75th percentiles; points are displayed as outliers if they are above 
or below 1.5 times the interquartile range.  
E. Control (sgNon-targeting#1) and SLC1A3 knockout (sgSLC1A3#4-1) PC3 cell lines were 
subcutaneously injected into Balb/c nude mice (cAnN/Rj) (n=8 per group). Once tumor volumes 
reached 50 mm3, mice were treated with mock (saline) or ASNase (60 U per day). Data was 
presented as mean ± SEM. 
 
Data information: Results were presented as mean ± SD, unless otherwise stated. The p-value was 
calculated by two-tailed unpaired t test from Prism7. *p<0.05, **p<0.01, ***p<0.001. 
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Figure EV2. Combination of ASNase and SLC1A3 inhibition impairs cancer cell 
proliferation. 
A. PC3 cells were incubated with two SLC1A3 inhibitors (UCPH-101 and TFB-TBOA) at indicated 
concentrations and subjected to an aspartate uptake assay (n=2). Leucine uptake level was used 
for normalization.  
B. PC3 cells were treated with ASNase (0.3 U/ml) and TFB-TBOA (5 M) as indicated and images 
were taken after 4 days. The scale bar indicates 300 m and cells highlighted in pink present 
apoptotic cells.  
C. PC3 cells were treated with mock or combination of ASNase (0.3 U/ml) and TFB-TBOA (5 M) for 
9 days and subjected to flow cytometry measurements of cell cycle using BrdU labelling. 
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 D. Flow cytometry cell cycle distribution analysis of PC3 cells under indicated conditions for 9 days 
by BrdU labeling. ASNase (0.3 U/ml) and TFB-TBOA (5 M). 
E. Representative images of apoptosis in DU145 and DU145-V5-SLC1A3 cells treated with ASNase 
(0.2 U/ml) and TFB-TBOA (5 M) as indicated, and subjected to IncuCyte analysis for apoptotic 
cells (highlighted in pink). The scale bar indicates 300 m. 
F. DU145 and DU145-V5-SLC1A3 cells were treated with ASNase (0.2 U/ml) and TFB-TBOA (20 
M) for 3 days as indicated, and collected for metabolome analysis by LC-MS to determine the 
relative levels of amino acids and metabolites involved in urea cycle, pyrimidines synthesis, TCA 
cycle, oxidation, glycolysis and carnitines. GLN: glutamine; ASN: asparagine; GLU: glutamate; 
ASP: aspartate; TCA cycle: tricarboxylic acid cycle; UMP: uridine monophosphate; CMP: cytidine 
monophosphate; PEP: phosphoenolpyruvate; NADH: nicotinamide adenine dinucleotide (reduced 
form); NAD+: nicotinamide adenine dinucleotide (oxidized form); NADPH: nicotinamide adenine 
dinucleotide phosphate (reduced form); NADP+: nicotinamide adenine dinucleotide phosphate 
(oxidized form); GSSG: glutathione disulfide; HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA; FAD: 
flavin adenine dinucleotide. 
 
Data information: Results were calculated based on three independent replicates, unless otherwise 
stated, and presented as mean ± SD. The p-value was calculated by two-tailed unpaired t test from 
Prism7. *p<0.05, **p<0.01, ***p<0.001.  
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 Figure EV3. Isotopic tracing of aspartate and glutamate in DU145-V5-SLC1A3 cells. 
DU145-V5-SLC1A3 cells were pretreated with ASNase (0.2 U/ml) for 48hrs and then supplemented 
with [13C4,15N] L-aspartate (1.5mM) and unlabeled glutamate (1.5mM), or [13C5,15N] L-glutamate 
(1.5mM) and unlabeled aspartate (1.5mM) for 8 hrs. Subsequently, cells were harvested for LC-MS 
analysis.  
A. Mass isotopologue analysis of 13C and 15N incorporation into asparagine and glutamine in 
DU145-V5-SLC1A3 cells cultured as indicated conditions. 
B. Mass isotopologue analysis of 13C and 15N incorporation into glutamine, glutamate and aspartate 
and metabolites from TCA cycle, urea cycle and nucleotide synthesis in DU145-V5-SLC1A3 cells 
cultured with [13C4,15N] L-aspartate and unlabeled glutamate. 
C. Mass isotopologue analysis of 13C and 15N incorporation into glutamine, glutamate and aspartate 
and metabolites from TCA cycle, urea cycle and nucleotide synthesis in DU145-V5-SLC1A3 cells 
cultured with [13C5,15N] L-glutamate and unlabeled aspartate.  
 
Data information: Data shown in (B–C) were calculated as labeled fraction divided by total peak area 
(including unlabeled fraction) and results were presented as mean ± SD (n=3). Number before brackets 
accounts for 13C incorporation and number in brackets accounts for 15N incorporation. The p-value was 
calculated by two-tailed unpaired t test from Prism7. *p<0.05, **p<0.01, ***p<0.001.  
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 Figure EV4. RT-qPCR validation of differential expressed genes in PC3, DU145 and 
DU145-V5-SLC1A3 Cells from Figure 4. 
A–C. RT-qPCR validation based on transcriptome analysis in PC3 (A), DU145 (B) and DU145-V5-
SLC1A3 cells (C).  
 
Data information: Results were calculated based on three independent replicates, and presented as 
mean ± SD. 
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 Figure EV5. SLC1A3 expression promotes ASNase resistance and tumor progression in 
vivo. 
A. Glutamine levels in serum, mammary fat pad tissues and growing tumors derived from 
SUM159PT human breast cancer cells with or without ASNase treatment (60 U per day) for 
consecutive 5 days. Essential amino acids were used for the raw data normalization. Results 
were presented as mean ± SEM (n=3). 
B. Left: quantification of aspartate uptake in parental 4T1 and 4T1-V5-SLC1A3 cells (n=2). Leucine 
uptake was used for normalization. The p-value was calculated by one-tailed unpaired t test in 
Prism7.  
Right: IncuCyte cell proliferation curves for parental 4T1 and 4T1-V5-SLC1A3 cells with or without 
ASNase (0.2 U/ml) for 10 days (n=3).  
C. Tumor volumes resulting from orthotopic implantation of parental 4T1 and 4T1-V5-SLC1A3 cells 
at day 12 (n=13 mice per group, except for 4T1+ASNase, n=12). Results were presented as 
mean ± SEM. 
D. Days for orthotopically injected parental 4T1 and 4T1-V5-SLC1A3 cells to reach 450–550 mm3. 
Results were presented as mean ± SEM (n=13). 
E. Following the mastectomy, mice were daily challenged for breathing test and sacrificed due to 
breathing problems. The survival rate for 4T1 and 4T1-V5-SLC1A3 injected mice was scored in 
Prism7.  
F. Left: quantification of aspartate uptake in MDA-MB-231 and MDA-MB-231-V5-SLC1A3 cells (n=2). 
Leucine uptake was used for normalization.  
Right: IncuCyte cell proliferation measurements for MDA-MB-231 and MDA-MB-231-V5-SLC1A3 
cells with or without ASNase (1 U/ml) for 8 days (n=3).  
 
Data information: Results were calculated based on three replicates and presented as mean ± SD (unless 
otherwise stated). The p-value was calculated by two-tailed unpaired t test except for (B) in Prism7. 
*p<0.05, **p<0.01, ***p<0.001. 
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Abstract 
  rroline- -carbo  late red ctase           is the final en  me in ol ed in the bios nthesis of 
proline and has been fo nd to be  pre  lated in  ario s forms of cancer    e to the role of 
proline in maintainin  the redo  balance of cells and pre entin  apoptosis,       is emer in  
as an attracti e oncolo   tar et   re io s        noc o t st dies led to a red ction in t mor 
 rowth  Accordin l , a small molec le inhibitor of       co ld lead to new treatments for 
cancer, and a foc sed screenin  effort identified par  line as a fra ment-li e hit  We report the 
desi n and s nthesis of the first tool compo nds as       inhibitors, deri ed from par  line, 
which were assa ed to assess their abilit  to atten ate the prod ction of proline  Str ct ral 
acti it  st dies ha e re ealed the  e  determinants of acti it , with the most potent compo nd 
     showin  impro ed acti it  in vitro in en  me             μ   and pathwa  rele ant effects in 
cell-based assa s  
 
 
  rroline- -carbo  late red ctase           is the final en  me in ol ed in the bios nthesis of 
proline from both  l tamic acid and ornithine, as o tlined in scheme     hristensen et al, 
    a    l tamic acid is firstl  phosphor lated b   l tamate  - inase      , before bein  
dephosphor lated b   amma- l tam l phosphate red ctase  γ-     to prod ce  l tamate-γ-
semialdeh de, which e ists in an e  ilibri m with p rroline- -carbo  late        Ornithine is 
also transformed to the same intermediate thro  h the action of ornithine amino transferase 
 OA        is then finall  red ced to proline b         sin  the red ced form of nicotinamide 
adenine din cleotide phosphate  NA     as a cofactor, altho  h in vitro nicotinamide adenine 
din cleotide  NA    can also ser e as a co-factor  
 
Scheme 1. The proline biosynthesis pathway (adapted from (Christensen et al, 2017b)). 
 
 roline is essential for protein s nthesis and pla s a role in the secondar  str ct re of proteins  
 his amino acid and its deri ati es are also the main resid es fo nd in colla en, the most 
ab ndant protein fo nd within the bod    han  et al,         owe er, it also pla s a role in 
maintainin  the redo  balance of cells thro  h a process  nown as the proline c cle   han  et 
al,     ;  ian  et al,     ;  anner et al,        
 
    is re enerated in the mitochondria b  the o idation of proline b  proline deh dro enase 
   O   ,  eneratin  adenosine triphosphate  A   , in the process  O tside of the 
mitochondria,     can be recon erted to proline   his prod ces a molec le of nicotinamide 
adenine din cleotide phosphate  NA     which is a ailable for  se b  the pentose-phosphate 
pathwa    he pentose-phosphate pathwa  will e ent all  prod ce ribose- -phosphate   - -  , 
which can be  sed to s nthesi e n cleotides or  nder o f rther transformations to e ent all  
 reach fr ctose- -phosphate   - -  , that is able to prod ce A   thro  h  l col sis   hese three 
process ha e an essential role in the s r i al and proliferation of cells  Son  et al,     ;  ane & 
 an,     ;  im et al,         he pentose-phosphate pathwa  also red ces NA    bac  to 
NA    which then s pports the dis lfide red ction s stem  ia thioredo in red ctase and 
 l tathione red ctase, minimi in  prod ction of reacti e o   en species   OS , a ain 
contrib tin  to cell s r i al  
 
 n health  cells, these processes are hi hl  re  lated and essential for maintainin  normal 
f nction   anner et al,         owe er, in certain cancers, s ch as breast, prostate and some 
l n  and s in cancers,       is fo nd to be  pre  lated   ra e et al,     ;  ai et al,     ; 
 in  et al,     ; de  n eniis et al,     ; Zen  et al,         his leads to hi her le els of proline 
and e acerbated effects of the proline c cle, with the cells effecti el   sin  this method to 
increase cell s r i al   anner et al,         f a method of red cin  or inhibitin        acti it  
co ld be disco ered, it co ld pro ide a new means of treatin  cancer  We and others ha e 
reported st dies in both breast cancer   oa  a-  ch et al,       and h man prostate  Zen  et 
al,       cell lines showin  that        noc o t ca ses phenot pic chan es in the cell   n the 
prostate cancer st dies, this res lted in an increase in cell c cle arrest and apoptosis in vitro, 
while in the breast cancer st dies a red ction in t mor si e in vivo was obser ed   hese 
e periments ha e shown that mod latin        directl  affects the s r i al rate of some 
cancers,  alidatin        as an emer in  oncolo   tar et  
 
While omission of a  ene is a  sef l tool in its own ri ht, the process is comple  and caref l 
selection of  ectors and deli er   ehicles are re  ired to minimi e inflammator  and off-tar et 
effects, which can ma e the process len th  and e pensi e  Sel ir ,     ;  an  et al,     ; 
 ian  et al,          rthermore,  ene therap  is not  et an officiall  appro ed treatment for an  
disease and  ntil more is  nown abo t the h man  enome, this is not li el  to be appro ed in 
the near f t re   etropo los et al,        A more tractable approach wo ld  tili e a small 
molec le tool compo nd, potentiall  leadin  to a new appro ed therap  for cancer treatment  
 
 n order to identif  a chemical startin  point, a commerciall  a ailable librar  of pharmace ticall  
acti e compo nds   O A ®    , Si ma Aldrich  was screened a ainst         ased on this 
screenin  campai n, par  line was identified as a fra ment-li e hit   ,  i        ar  line had a 
modest      of     μ , howe er, displa ed an enco ra in  li and efficienc       of        hen 
et al,         
  
Fig. 1. Structure and activity of pargyline. 
 
 hese considerations, co pled with its low molec lar wei ht, made it an attracti e fra ment-li e 
hit and a n mber of analo  es were prepared in order to assess the str ct re acti it  
relationship  SA    Startin  from the appropriate amine, the tar et analo  es were s nthesi ed 
 ia al  lation or red cti e amination with the correspondin  bromide or aldeh de, respecti el , 
as o tlined in Scheme    
 
Scheme 2. A: Alkylation conditions; bromide (0.25 mmol), amine (0.25 mmol), acetonitrile (0.8 M), with 
potassium iodide added for less activated bromides. B: Reductive amination conditions; aldehyde (3 
mmol), amine (1 mmol), acetic acid (1 mmol), dry dichloromethane (0.05 M) then sodium 
triacetoxyborohydride (3 mmol). 
 
 he mod lar str ct re of par  line ma es it amenable to tar eted elaboration of three principal 
re ions: the ben  l, N-meth l and propar  l  ro ps  As no cr stallo raphic information of the 
bindin  site par  line occ pies within       was a ailable, a stepwise approach was adopted 
in order to assess the impact of chan in  these s bstit ents on en  me inhibition  sin  the in 
vitro compo nd screenin  assa   
 
 nitiall , chan es to the ben  l  ro p were e amined    e to their relati e ab ndance in 
pharmace ticall  acti e compo nds, the presence of halo ens in  ario s positions aro nd the 
phen l rin  of the ben  l  ro p was assessed first   i    A    ord &  o,         leasin l  
almost all of the compo nds were fo nd to be more acti e than par  line in       inhibition, 
with the e ception of the  -fl oro,  -chloro and  -bromo deri ati es   ,   and  , respecti el   
which showed red ced acti it    t was also fo nd that the infl ence on acti it  was  reatest 
when the halo en was in the  -position   –   and wea est in the  -position    and   , with the 
 -position bein  between the two potencies    and      he si e of the halo en in the  -position 
 was also fo nd to ha e an effect with a  eneral increase in potenc  obser ed mo in  down the 
 ro p   –  , with the optim m bein  the  -bromo s stem, which was  er  similar in potenc  to 
the  -iodo moiet , with both of these s rpassin  the  -chloro deri ati e  
 
 n order to follow  p on these obser ations, a n mber of different f nctional  ro ps on the 
ben  l rin  were st died, as shown in  i       A ran e of electron donatin  and withdrawin  
 ro ps were anal  ed in  ario s positions aro nd the rin   A ain, the  -position was fa ored 
with a similar pattern of acti it  bein  obser ed with the nitro  ro p    –    as with the 
halo ens   nfort natel , none of the compo nds matched the potenc  of compo nd  , with no 
clear preference for electron donatin     –    or withdrawin   ro ps    –    noted from 
this st d   
 
With more potent analo  es obser ed with increasin  si e of halo en, it was reasoned that 
lar er  ro ps on the ben  l rin  co ld also res lt in an increase in potenc     e to the 
similarities in  ol me of iodine and phen l moieties  Stepan et al,      , some biphen ls     
and     were prepared b  S    i co plin  of compo nd     nfort natel , these analo  es were 
less acti e than both par  line and compo nd  , s   estin  that there are other properties 
be ond the si e of s bstit ent contrib tin  to the increase in potenc    his co ld be lin ed to a 
halo en bondin  effect, where the stren th of an interaction increases with the si e of the 
halo en atom, as obser ed with analo  es  –    ord &  o,        
 
 ompo nd   was fo nd to ha e the hi hest potenc , also impro in  the   , showin  that the 
presence of a bromine atom on the  -position of the ben  l  ro p ma  be beneficial to bindin   
With the pre io s e emplars onl  representin  a sin le s bstit tion on the ben  l  ro p, it was 
decided to incorporate a  ariet  of dis bstit ted analo  es as shown in  i        nitiall , this 
was probed  sin  dichloroben  l moieties d e to their s nthetic a ailabilit    n comparison to 
compo nd  , ha in  s bstit tion of the  - and  -positions res lted in a compo nd with a similar 
potenc  to the monos bstit ted  -position, while the  , - and  , - deri ati es  compo nds 
   and   , respecti el   were inacti e  
 
  chan in  the  -chloro of compo nd    for a trifl orometh l  ro p      res lted in a less 
acti e compo nd, a ain s   estin  the importance of halo ens   owe er, the  , -dichloro 
species    had a m ch  reater potenc  than compo nd   and a similar potenc  to compo nd    
 his was s rprisin  as a monos bstit ted compo nd in the  -position was fo nd to be the least 
 acti e re ioisomer in the initial halo en screen    and      his increase in potenc  co ld be d e 
to an e tra interaction at the, as  et  n nown, bindin  site of the en  me which complements 
the interaction at the  -position  Other dis bstit ted modifications    –    and naphth l      
res lted in lower le els of acti it   
 
 he final modifications to the ben  l  ro p in ol ed e chan in  it for a completel  different 
f nctional handle to assess its necessit  for acti it , as o tlined in  i        omolo ation      
and e chan e of the  -membered ben  l  ro p for  -membered heteroc cles     and     
res lted in compo nds that were inacti e, indicatin  that the ben  l  ro p is essential for 
acti it    ncorporation of a branched meth l in the ben  l position      red ced the acti it  of the 
compo nd, s   estin  that there ma  be a steric clash at the bindin  site   
  
  i      A: SAR of halogen substitutions (blue). B: SAR of non-halogen substitutions (blue). C: SAR of 
disubstitutions (blue). D: SAR of non-benzyl substitutions (blue). a Prepared by Suzuki-Miyaura cross-
coupling. 
 
With the  -bromoben  l moiet  identified as the optimal  ro p for       inhibition, and this 
motif was carried on thro  ho t the rest of the SA  e ploration  
 
 he second  ro p assessed was the N-meth l moiet  as o tlined in  i       here was mar edl  
less tolerance in this  ro p than with the ben  l  ro p with onl  fo r analo  es showin  an  
meas rable acti it  a ainst the en  me   arbon chains lon er than an eth l  ro p     and 
    were fo nd to be inacti e as were branched moieties     and       ndeed, of the al  l 
s bstit ents onl  eth l      was acti e, albeit less so than the meth l s bstit ent of compo nd 
    a in  no s bstit ent on the nitro en core      also res lted in a less potent compo nd  
 ar er  ro ps s ch as  -bromo ben  l      and iso a ol l      were moderatel  acti e  
 owe er, the hi her molec lar wei ht of these compo nds, res lted in a lower      ar er 
s bstit ents s ch as    were fo nd not to be tolerated   etherin  the N- ro p to the ben  l 
 ro p was also not tolerated with the isoindoline and tetrah droiso  inoline     and   , 
respecti el   both bein  inacti e   his co ld be d e to the molec les bein  constrained in the 
wron  conformation for bindin  to the tar et   he final chan es assessed were to the nat re of 
the nitro en core, with the introd ction of an amide      or s lfonamide      in the place of a 
basic tertiar  amine   oth of these were inacti e s   estin  that a basic amine is necessar  for 
acti it   
  
Fig. 3. Structure and activity of alterations to the N-methyl group (red). 
 
 he last modifications e amined were alterations to the propar  l moiet , as o tlined in  i      
As with the N-meth l  ro p, there was limited tolerance in chan es to this  ro p    ll  red cin  
     or completel  remo in  the propar  l  ro p      res lted in inacti e deri ati es, while 
red ction to the propen l analo  e      drasticall  red ced acti it    ntrod ction of a ben  l      
and c cloprop l  ro p      also res lted in inacti e compo nds and s   ests the al  ne 
component of the molec le is re  ired   omolo ation      and incorporation of a branched 
meth l to the propar  l  nit      res lted in a considerable red ction in potenc    n the case of 
the branched analo  e, this co ld be d e to a steric restriction in the bindin  site, howe er, 
f rther cements the need for a propar  l amine for optim m potenc    inall , the terminal al  ne 
was e chan ed for internal al  nes    and      leasin l , these compo nds retained some 
de ree of potenc  which decreased when the si e of the cappin   ro p increased   owe er, 
the  remained less potent than compo nd  , which a ain co ld be attrib ted to a steric 
 constraint   t sho ld be noted that f rther str ct ral data wo ld be re  ired to corroborate this 
h pothesis  
 
Fig. 4. Structure and activity of changes to the propargyl group (purple). aCommercially available 
feedstock. 
 
 
 ompo nd   was fo nd to be the most acti e of all the analo  es s nthesi ed and accordin l  
was ad anced for f rther biolo ical e al ation as the lead compo nd  
 
 he first st d  considered was meas rement of endo eno s proline le els b    - S  As the 
inhibition of       sho ld pre ent the formation of proline, compo nd   sho ld lower the 
concentration of intracell lar proline   h s, a h man breast cancer cell line  S     -    was 
inc bated with compo nd   at serial concentrations of  ,  ,    and     μ , respecti el , with 
par  line      μ   as a positi e control  As o tlined in  i    a, par  line s pplementation at a 
concentration of     μ  co ld red ce endo eno s proline le el b  appro imatel      
compared to moc  treatment   ntri  in l , compo nd   e en at   μ  co ld alread  stron l  
red ce proline le els despite the inhibition was somehow impaired at hi her concentration of 
    μ    he increase in proline le els mi ht be attrib ted to the limited sol bilit  of compo nd   
in the b ffer at hi her concentrations  Notabl , almost no effect on the le els of other amino 
acids was detected with either par  line or compo nd     i   S , S pplementar   aterial    n 
order to show if the red ction of proline was d e to       inhibition, we performed a    -
 l tamine tracin  e periment     c lt rin  cells with   -    - l tamine, we followed the 
 incorporation of     from  l tamine,  ia  l tamate, in proline      , as shown in  i    b  After 
   h inc bation with compo nd  , proline deri ed from labeled  l tamine       is less 
presented compared to moc  treatment   hese data f rther confirmed that compo nd   co ld 
inhibit       acti it  and th s lead to lower endo eno s proline le el  
 
Fig. 5. (a) Results of the LC–MS based amino acid assay, showing the quantity of proline present in 
lysed human breast cancer cells (SUM159-PT) after incubation with pargyline and compound 4. (b) 
Results of the glutamine flux study showing lower levels of proline (M+5) after incubation with compound 
     μ    
  
All the abo e data indicates that both par  line and compo nd   co ld inhibit      , th s 
ca sin  a meas rable, pathwa  rele ant, biolo ical response   o the best of o r  nowled e, this 
represents the first time s ch a phenot pic response has been obser ed  sin  small molec les 
as       inhibitors  
 
 o e amine the effecti it  of compo nd    nder cell c lt re conditions, two breast cancer cell 
lines,   A-  -    and S     -  , were separatel  inc bated with or witho t compo nd    
 oth cell lines ha e relati el  hi h       le els, and depend on       acti it  for 
proliferation and t mor formation   oa  a-  ch et al,         nterestin l , followin  the 
inc bation of compo nd       μ  , cell proliferation of both   A-  -    and S     -   was 
impaired  data not shown   As e pected, the s pplementation of proline to the medi m resc ed 
the ad erse effect of compo nd     
 
 n concl sion, o er    potential small molec le inhibitors of       were s nthesi ed in order to 
probe the SA  aro nd       inhibition  Of all the s nthesi ed analo  es, compo nd   
 termed  roline  rod ction  nhibitor- ,  ro  -   was identified as the most potent in the       
inhibition assa  with an      of     μ , appro imatel     times more potent than that of 
par  line, with the most efficient bindin  as e idenced b  a    of       As a res lt of this,  ro  -
  was ta en forward as a lead into a series of pathwa  rele ant biolo ical tests and, was fo nd 
to si nificantl  red ce endo eno s proline le el and inhibit cancer cell proliferation    rther 
wor  is to obtain an  -ra  cr stal str ct re of  ro  -  and      , as well as  alidation of the 
efficac  of       inhibitor,  ro   in vivo  
 
Supplementary data (Experimental procedures and characterization data of all pargyline 
analogues and protocol for PYCR1 testing) to this article can be found online at 
https://doi.org/10.1016/j.bmcl.2019.07.047. 
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 Chapter 5  
General Discussion 
 
The potential of L-asparaginase in treating solid tumors still needs to be further explored 
L-asparaginase (ASNase) has achieved great success in treating childhood acute lymphoblastic 
leukemia (ALL)1. Till now, it is the only FDA approved drug for amino acid deprivation in clinic. 
Notably, ASNase has a dual asparagine and glutamine deaminase activity even though the 
glutaminase activity was not required for its anticancer effect with ASNS-negative cancer cells2. 
We observed that in cell culture conditions, both asparagine and glutamine were robustly 
depleted by ASNase while in vivo conditions, the efficacy to deplete glutamine was far less 
effective compared to that of asparagine3. And the potent capability to deplete asparagine in 
tissues and expanding tumors by ASNase was absolutely impressive3, which leaves space to 
explore cancer vulnerability under asparagine depletion conditions by ASNase.   
 
ASNS is essential but not sufficient for ASNase resistance 
Asparagine synthetase (ASNS) was the gene responsible for the endogenous asparagine 
synthesis. Accordingly, under asparagine depletion by ASNase, ASNS expression was taken for 
granted to be the reason for ASNase resistance4. However, this was somehow controversial: 
first of all, researchers found that ASNase was still effective with ALL even though ASNS was 
expressed5,6; secondly, the upregulated ASNS could not synthesize enough asparagine to 
compensate for the depletion by ASNase3. Protein degradation for asparagine supply has been 
proposed to contribute to ASNase resistance in ALL, again, whether this could produce enough 
asparagine to rescue the severe asparagine depletion by ASNase treatment, and whether the 
newl  “prod ced” asparagine was still available in the presence of ASNase (probably 
immediately degraded) needs to be further investigated7. Despite some reported the effectivity 
of ASNase in ASNS-negative solid tumors, we proposed that the activation of general amino 
acid sensing axis GCN2-ATF4-ASNS was an essential response to ASNase treatment, or other 
amino acid starvation or nutrient depletion, which was not sufficient to reduce the resistance3,8–
10. 
 
SLC1A3 mediated aspartate/glutamate uptake contributed to ASNase resistance 
By performing a genome-wide drop-out screen, we found the loss of function of SLC1A3, a 
cytoplasmic transporter for aspartate/glutamate, could sensitize cancer cells to ASNase 
resistance3. This was interesting and reasonable as aspartate and glutamate were exactly the 
 substrates for endogenous synthesis of asparagine and glutamine, which could be degraded by 
ASNase. Besides, we observed that following ASNase treatment, PC3 cells presented 
increased consumption of aspartate and glutamate to maintain cell proliferation. SLC1A3 
blockage in combination with ASNase treatment caused either cell cycle arrest or apoptosis in 
cancer cells which were originally resistant to ASNase. Meanwhile, we also observed 
compromised function of TCA cycle, urea cycle, nucleotide synthesis, energy production, redox 
homeostasis and lipid biosynthesis. Notably, the specific expression pattern of SLC1A3 in brain 
tissue under normal conditions might supply a specific target for tumors. Recently, the role of 
aspartate has gained so much attention that the involvement of glutamate in cancer progression 
was largely ignored11–14. This was biased as: (1), aspartate and glutamate could be converted 
mutually; and (2), the transportation of aspartate was usually coupled with exchange with 
glutamate. Overall, our findings were in consistency with a previous study, where aspartate 
metabolism was predicted for ASNase resistance in primary ALL samples15. 
 
Overall, CRISPR screens serve as an efficient platform to target cancer vulnerability, which 
might help to improve drug performance or identification of new drugs for cancer therapeutic 
purpose in clinic. Restricting onco-amino acids or other nutrients by interference either with 
corresponding transportation or endogenous synthesis, or even in combination if necessary, 
might provide a potential strategy for cancer treatment.  
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 Summary 
 
Early in 1961, L-asparaginase (ASNase), originated from guinea pig serum, was found to have 
anti-lymphoma effect and later on it was approved by the Food and Drug Administration (FDA), 
and incorporated for acute lymphoblastic leukemia treatment. So far, the progress of ASNase in 
childhood ALL is quite impressive, with an overall survival rate of ~90%. This had greatly 
encouraged further application of ASNase in other tumor types. However, several clinical trials 
indicated severe toxicity of ASNase due to increasing dosage. Asparagine synthetase (ASNS) 
was canonically proposed to be responsible for ASNase resistance. However, we thought the 
general nutrient sensing machinery (GCN2-ATF4-ASNS axis) as a common and essential 
response to nutrient starvation but not sufficient to induce this resistance. Hence, it was of great 
interests to investigate if other genes or pathways were involved in ASNase response besides 
the GCN2-ATF4-ASNS axis.  
 
In this thesis, we initiated a genome-wide CRISPR functional screen in PC3 cells and identified 
SLC1A3 as a contributor to ASNase resistance. SLC1A3 was normally and restrictedly 
expressed in brain tissues. Interestingly, high SLC1A3 expression was also observed in some 
tumor types. This specific expression pattern might benefit drug target effectivity.  
 
Notably, except for amino acid, lipid-related metabolites could also be imported by 
corresponding transporters, indicating investigation on transporter(s) mediated nutrient convey 
might be urgent for our understanding of cancer metabolism and malignancy. And the pathways 
of endogenous synthesis of onco-amino acids or other nutrients that support cancer progression 
could also be critical targets for therapeutic purpose.   
 
Besides, we also explored the development of inhibitors targeting proline endogenous synthesis 
and examined their effects on cancer cell proliferation.  
 
In summary, restricting the availability of onco-amino acids might impair cancer cell malignancy 
and thus provide further clues for clinical research. 
 
 
 
 
 Samenvatting 
 
Begin 1961 bleek L-asparaginase (ASNase), afkomstig van cavia-serum, een anti-
lymfoomeffect te hebben en later werd het goedgekeurd door de Food and Drug Administration 
(FDA) en opgenomen voor acute lymfoblastaire leukemiebehandeling. Tot nu toe is de 
voortgang van ASNase in ALL bij kinderen behoorlijk indrukwekkend, met een algemeen 
overlevingspercentage van ~ 90%. Dit had de verdere toepassing van ASNase in andere 
tumortypen enorm gestimuleerd. Verschillende klinische onderzoeken wezen echter op ernstige 
toxiciteit van ASNase als gevolg van de toenemende dosering. Asparagine synthetase (ASNS) 
is volgens de canoniek verantwoordelijk voor ASNase resistentie. We dachten echter dat de 
algemene machines voor het meten van voedingsstoffen (GCN2-ATF4-ASNS-as) een 
veelvoorkomende en essentiële reactie waren op uithongering van voedingsstoffen, maar niet 
voldoende om deze weerstand te induceren. Daarom was het van groot belang om te 
onderzoeken of naast de GCN2-ATF4-ASNS-as andere genen of paden betrokken waren bij 
ASNase-respons. 
 
In dit proefschrift hebben we een genoom breed CRISPR-functioneel scherm in PC3-cellen 
geïnitieerd en SLC1A3 geïdentificeerd als een bijdrage aan ASNase-resistentie. SLC1A3 werd 
normaal en beperkt tot expressie gebracht in hersenweefsels. Interessant is dat bij sommige 
tumortypen ook hoge SLC1A3-expressie werd waargenomen. Dit specifieke expressiepatroon 
kan de doelgerichtheid van het geneesmiddel ten goede komen.  
 
Met name, met uitzondering van aminozuur, kunnen lipide-gerelateerde metabolieten ook 
worden geïmporteerd door overeenkomstige transporters, wat aangeeft dat onderzoek naar 
door transporter(s) gemedieerde nutriëntentransport mogelijk dringend is voor ons begrip van 
het metabolisme van kanker en maligniteit. En de routes van endogene synthese van onco-
aminozuren of andere voedingsstoffen die de progressie van kanker ondersteunen, kunnen ook 
kritische doelen zijn voor therapeutische doeleinden. 
 
Daarnaast hebben we ook de ontwikkeling van remmers gericht op endogene proline-synthese 
onderzocht en hun effecten op de proliferatie van kankercellen onderzocht. 
 
Samenvattend kan het beperken van de beschikbaarheid van onco-aminozuren de maligniteit 
van kankercellen verminderen en zo verdere aanwijzingen geven voor klinisch onderzoek. 
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